Answers are grounded in this paper and cite their sources.
Introduction: The updated S2K GERD Guideline (2023) recommends PPI therapy of 4-8 weeks’ aiming to reduce unnecessary long-term use and potential adverse events, where an appropriate long-term indication is absent. Doses of long-term PPI should be regularly reviewed for minimum effective dose. Objective: This study aims to assess the impact of targeted educational intervention on recent guidelines, using a General Practitioner (GP) alerting system at point of prescription. The study also sorts to identify patient prescribed PPIs while observing PPI prescription patterns pre and post guideline release. [ 1 ] [ 2 ]] Methods: A 12-month non-interventional real-world study on leveraging GP alerting messages in the electronic medical record (EMR) containing short messages on guideline recommendations and peer-reviewed publications on PPI limitation and alternative treatment in the management of GERD and upper GI conditions. Baseline was January to March 2023. The study spans 54% of GP practices in Germany with anonymised prescription data of 2400 practices. Data analysis was conducted in patients with ICD codes for uncomplicated reflux and diagnosed GERD, to determine impact of this intervention on PPI prescription by comparing prescription numbers, pack sizes, diagnosis codes and number of GPs. Results: In the study period, on average 333 messages were issued and 65 GPs were reached for diagnosed GERD and uncomplicated reflux. A variation in number of GPs was reached, but analysis revealed significant difference in high numbers of PPI prescriptions without indicated diagnosis; mean difference of 15 GPs against those with diagnosis code (95%Cl: 9.7-20.10; P<0.001) for uncomplicated reflux and 47 GPs for diagnosed GERD (95%Cl: 19.7-74.3; P<0.0017). The ratio of patients with an ICD code per GP ranged from 0.34 to 0.47 for uncomplicated reflux and diagnosed GERD. Less than 50% had documented diagnosis for PPI use. Patients diagnosed with GERD, rose by 10% from Q1 to Q4. Large pack sizes were prescribed for both patients (ICD12) and (ICD K21.0 & K21.9). Post intervention the prescription of PPI >3 months was 86% for diagnosed GERD and 100% for uncomplicated reflux. Both patient groups were often prescribed doses higher than 20mg. Confirmed by Plehhova 2023 , 80% of PPI prescriptions >3 months and Rückert-Eheberg 2022 describing high numbers of off-label use in Bavaria. Fig. 1 Conclusion: Findings from this study suggest that a significant proportion of PPI prescriptions do not align with current guideline recommendations. This emphasises the need for continuous and multidimensional improvement strategies and interventions on alignment of prescribing practice with guidelines, particularly in high-pressure primary care settings. Publication History Article published online: 26 September 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
No takes yet. Share an insight, caveat, or question.
Plehhova et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: